N
HZNP

Nuveen’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Nuveen’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-36,000
Closed -$4K – 3471
2021
Q3 		$4K Buy
+36,000
New +$3.74M ﹤0.01% 3399
2021
Q2 		– Sell
-84,400
Closed -$8K – 3662
2021
Q1 		$8K Buy
+84,400
New +$7.12M ﹤0.01% 3310

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Nuveen's HZNP Position: Q4 2023 in Review

Nuveen sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 849,393 shares — an estimated $98.3M sold.

Nuveen first reported a position in HZNP in Q2 2016 and held it in 30 quarters. The position peaked at $759M in Q4 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Nuveen reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Nuveen sold 849,393 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $98.3M.
  • Nuveen first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 30 quarters.
  • Nuveen's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $759M in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Nuveen's 13F filing for Q4 2023, filed 14 Feb 2024.